Acuta Capital Partners, LLC Athira Pharma, Inc. Transaction History

Acuta Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.74 - $13.43 $383,682 - $1.88 Million	-140,030 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$8.96 - $13.51 $1.52 Million - $2.3 Million	-170,000 Reduced 54.83%	140,030 $1.89 Million
Q4 2021 Feb 14, 2022	BUY	$9.17 - $16.39 $116,165 - $207,628	12,668 Added 4.26%	310,030 $4.04 Million
Q3 2021 Nov 15, 2021	SELL	$9.15 - $11.09 $1.19 Million - $1.44 Million	-129,698 Reduced 30.37%	297,362 $2.79 Million
Q2 2021 Aug 16, 2021	BUY	$10.24 - $20.87 $277,094 - $564,742	27,060 Added 6.77%	427,060 $4.37 Million
Q1 2021 May 17, 2021	BUY	$16.9 - $29.77 $118,299 - $208,390	7,000 Added 1.78%	400,000 $7.36 Million
Q4 2020 Feb 16, 2021	BUY	$16.48 - $34.3 $502,640 - $1.05 Million	30,500 Added 8.41%	393,000 $13.5 Million
Q3 2020 Nov 16, 2020	BUY	$16.02 - $18.46 $5.81 Million - $6.69 Million	362,500 New	362,500 $6.69 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $24.2M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.